*️⃣CT-P13=1st monoclonal biosimilar to infliximab (IFX) ⭐️ReFLECT: 1370 French pts (142 RA, 411 axSpA, 96 PsA) →2 groups: IFX-naïve starting CT-P vs switching from IFX to CT-P *️⃣CT-P13 induced improvement in IFX-naïve & maintained dz in pts switched Abst#0817 #ACR21 @RheumNow https://t.co/bASmGvhuIS